Adam Schwaid

Adam Schwaid has extensive work experience in chemical biology and chemoproteomics. Adam is currently working as the Director of Chemical Biology and Proteomics at Odyssey Therapeutics, starting in October 2021. Prior to that, they worked at Merck as an Associate Principal Scientist and Senior Scientist from January 2016 to October 2021. At Merck, they focused on identifying targets from phenotypic screens, understanding compound mechanism of action, and developing new chemoproteomic technologies. Before joining Merck, Adam worked at Pfizer as a Senior Scientist from September 2013 to February 2016, where they contributed to chemical biology research in the CVMED research unit. Adam also has a Ph.D. in Chemistry and Chemical Biology from Harvard University, where they conducted research on short peptides and orphan nuclear receptor ligands. Additionally, they worked as a Teaching Fellow at Harvard University and as a Research Assistant at New York University.

Adam Schwaid attended Harvard University from 2006 to 2013, where they obtained a Bachelor's degree in Biochemistry in 2009, followed by a Master's degree and a Ph.D. in Chemistry and Chemical Biology in 2009 and 2013 respectively.